Drugs & Targets FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves Revtorpyk for HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves companion diagnostic for Opdivo for ESCC and GEJ, gastric, and esophageal adenocarcinoma July 17, 2026Vol.52 No.28
Drugs & Targets FDA issues CRL for rivoceranib + camrelizumab as a first-line treatment for unresectable or metastatic HCC July 17, 2026Vol.52 No.28
News Analysis A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. July 10, 2026Vol.52 No.27By Jacquelyn Cobb
Capitol Hill OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill July 10, 2026Vol.52 No.27By Paul Goldberg
Trials & Tribulations Saving Western Kenya’s pediatric blood cancer patientsHow flow cytometry is changing the diagnostic landscape July 10, 2026Vol.52 No.27By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo
Trials & Tribulations The challenge of making the move from conversational AI to autonomous scientific discoveryAdvancing from level II to level III AI agents in precision medicine July 10, 2026Vol.52 No.27By Enrique Velazquez-Villarreal
Cancer Policy FDA halts public release of Complete Response Letters, following citizen petition July 10, 2026Vol.52 No.27By Claire Marie Porter
